Overview

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

Status:
Completed

Trial end date:
2019-03-29

Target enrollment:

Participant gender:

Summary

This study is being conducted to determine if the uptake of anti-HIV medications called Genvoya® and darunavir is different at several body sites, including mucosal tissues.

Phase:

Phase 1

Details

Lead Sponsor:

Emory University

Collaborator:

Centers for Disease Control and Prevention

Treatments:

Anti-Retroviral Agents
Darunavir
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination